Influence of voiding dysfunction on the outcome of endoscopic treatment for vesicoureteral reflux

Nicola Capozza, Alberto Lais, Ennio Matarazzo, Simona Nappo, Mario Patricolo, Paolo Caione

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Purpose: Some patients with vesicoureteral reflux also experience voiding dysfunction. Dextranomer/hyaluronic acid copolymer (Deflux, Q-MED AB, Uppsala, Sweden) is an effective endoscopic treatment for vesicoureteral reflux. In an open label study we investigated the effect of voiding dysfunction on the efficacy of endoscopic treatment with dextranomer/hyaluronic acid copolymer in patients with vesicoureteral reflux. Materials and Methods: A total of 320 children 3 to 11 years old with grade II to IV vesicoureteral reflux confirmed by voiding cystourethrography underwent endoscopic treatment with dextranomer/hyaluronic acid copolymer. Of the patients 50 were re-treated with dextranomer/hyaluronic acid copolymer because of persistent reflux (grade II or greater). The first implantation technique was recorded on videotape. Voiding cystourethrography and micturition details were recorded at the 3 to 6-month followup visit and compared with baseline measurements. Results: At baseline 13 patients had known voiding dysfunction and 18 were misdiagnosed as not having voiding dysfunction. Of the 50 patients who required re-treatment, the initial implant was correctly positioned in 45 according to the videotape. Endoscopic observation at the time of re-treatment revealed no evidence of the implant in 15 patients. The implant was displaced in 27 patients and remained correctly positioned in 3. A total of 27 patients had voiding dysfunction, the majority of whom had urgency and frequency incontinence, had not received any anticholinergic therapy and had a displaced implant. Conclusions: Uncontrolled voiding dysfunction contributed to endoscopic treatment failure with dextranomer/hyaluronic acid copolymer in our series. Therefore, we suggest that patients with voiding dysfunction be treated at least 6 months before endoscopic therapy with anticholinergics and/or micturition rehabilitation.

Original languageEnglish
Pages (from-to)1695-1698
Number of pages4
JournalJournal of Urology
Volume168
Issue number4 II
Publication statusPublished - Oct 2002

Fingerprint

Vesico-Ureteral Reflux
Videotape Recording
Urination
Cholinergic Antagonists
Therapeutics
Diagnostic Errors
Treatment Failure
Sweden
Rehabilitation
Observation
dextranomer-hyaluronic acid copolymer

Keywords

  • Child
  • Dextrans
  • Hyaluronic acid
  • Urinary incontinence
  • Vesico-ureteral reflux

ASJC Scopus subject areas

  • Urology

Cite this

Influence of voiding dysfunction on the outcome of endoscopic treatment for vesicoureteral reflux. / Capozza, Nicola; Lais, Alberto; Matarazzo, Ennio; Nappo, Simona; Patricolo, Mario; Caione, Paolo.

In: Journal of Urology, Vol. 168, No. 4 II, 10.2002, p. 1695-1698.

Research output: Contribution to journalArticle

@article{fc9d8e094f034d998976685c76cb9c69,
title = "Influence of voiding dysfunction on the outcome of endoscopic treatment for vesicoureteral reflux",
abstract = "Purpose: Some patients with vesicoureteral reflux also experience voiding dysfunction. Dextranomer/hyaluronic acid copolymer (Deflux, Q-MED AB, Uppsala, Sweden) is an effective endoscopic treatment for vesicoureteral reflux. In an open label study we investigated the effect of voiding dysfunction on the efficacy of endoscopic treatment with dextranomer/hyaluronic acid copolymer in patients with vesicoureteral reflux. Materials and Methods: A total of 320 children 3 to 11 years old with grade II to IV vesicoureteral reflux confirmed by voiding cystourethrography underwent endoscopic treatment with dextranomer/hyaluronic acid copolymer. Of the patients 50 were re-treated with dextranomer/hyaluronic acid copolymer because of persistent reflux (grade II or greater). The first implantation technique was recorded on videotape. Voiding cystourethrography and micturition details were recorded at the 3 to 6-month followup visit and compared with baseline measurements. Results: At baseline 13 patients had known voiding dysfunction and 18 were misdiagnosed as not having voiding dysfunction. Of the 50 patients who required re-treatment, the initial implant was correctly positioned in 45 according to the videotape. Endoscopic observation at the time of re-treatment revealed no evidence of the implant in 15 patients. The implant was displaced in 27 patients and remained correctly positioned in 3. A total of 27 patients had voiding dysfunction, the majority of whom had urgency and frequency incontinence, had not received any anticholinergic therapy and had a displaced implant. Conclusions: Uncontrolled voiding dysfunction contributed to endoscopic treatment failure with dextranomer/hyaluronic acid copolymer in our series. Therefore, we suggest that patients with voiding dysfunction be treated at least 6 months before endoscopic therapy with anticholinergics and/or micturition rehabilitation.",
keywords = "Child, Dextrans, Hyaluronic acid, Urinary incontinence, Vesico-ureteral reflux",
author = "Nicola Capozza and Alberto Lais and Ennio Matarazzo and Simona Nappo and Mario Patricolo and Paolo Caione",
year = "2002",
month = "10",
language = "English",
volume = "168",
pages = "1695--1698",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4 II",

}

TY - JOUR

T1 - Influence of voiding dysfunction on the outcome of endoscopic treatment for vesicoureteral reflux

AU - Capozza, Nicola

AU - Lais, Alberto

AU - Matarazzo, Ennio

AU - Nappo, Simona

AU - Patricolo, Mario

AU - Caione, Paolo

PY - 2002/10

Y1 - 2002/10

N2 - Purpose: Some patients with vesicoureteral reflux also experience voiding dysfunction. Dextranomer/hyaluronic acid copolymer (Deflux, Q-MED AB, Uppsala, Sweden) is an effective endoscopic treatment for vesicoureteral reflux. In an open label study we investigated the effect of voiding dysfunction on the efficacy of endoscopic treatment with dextranomer/hyaluronic acid copolymer in patients with vesicoureteral reflux. Materials and Methods: A total of 320 children 3 to 11 years old with grade II to IV vesicoureteral reflux confirmed by voiding cystourethrography underwent endoscopic treatment with dextranomer/hyaluronic acid copolymer. Of the patients 50 were re-treated with dextranomer/hyaluronic acid copolymer because of persistent reflux (grade II or greater). The first implantation technique was recorded on videotape. Voiding cystourethrography and micturition details were recorded at the 3 to 6-month followup visit and compared with baseline measurements. Results: At baseline 13 patients had known voiding dysfunction and 18 were misdiagnosed as not having voiding dysfunction. Of the 50 patients who required re-treatment, the initial implant was correctly positioned in 45 according to the videotape. Endoscopic observation at the time of re-treatment revealed no evidence of the implant in 15 patients. The implant was displaced in 27 patients and remained correctly positioned in 3. A total of 27 patients had voiding dysfunction, the majority of whom had urgency and frequency incontinence, had not received any anticholinergic therapy and had a displaced implant. Conclusions: Uncontrolled voiding dysfunction contributed to endoscopic treatment failure with dextranomer/hyaluronic acid copolymer in our series. Therefore, we suggest that patients with voiding dysfunction be treated at least 6 months before endoscopic therapy with anticholinergics and/or micturition rehabilitation.

AB - Purpose: Some patients with vesicoureteral reflux also experience voiding dysfunction. Dextranomer/hyaluronic acid copolymer (Deflux, Q-MED AB, Uppsala, Sweden) is an effective endoscopic treatment for vesicoureteral reflux. In an open label study we investigated the effect of voiding dysfunction on the efficacy of endoscopic treatment with dextranomer/hyaluronic acid copolymer in patients with vesicoureteral reflux. Materials and Methods: A total of 320 children 3 to 11 years old with grade II to IV vesicoureteral reflux confirmed by voiding cystourethrography underwent endoscopic treatment with dextranomer/hyaluronic acid copolymer. Of the patients 50 were re-treated with dextranomer/hyaluronic acid copolymer because of persistent reflux (grade II or greater). The first implantation technique was recorded on videotape. Voiding cystourethrography and micturition details were recorded at the 3 to 6-month followup visit and compared with baseline measurements. Results: At baseline 13 patients had known voiding dysfunction and 18 were misdiagnosed as not having voiding dysfunction. Of the 50 patients who required re-treatment, the initial implant was correctly positioned in 45 according to the videotape. Endoscopic observation at the time of re-treatment revealed no evidence of the implant in 15 patients. The implant was displaced in 27 patients and remained correctly positioned in 3. A total of 27 patients had voiding dysfunction, the majority of whom had urgency and frequency incontinence, had not received any anticholinergic therapy and had a displaced implant. Conclusions: Uncontrolled voiding dysfunction contributed to endoscopic treatment failure with dextranomer/hyaluronic acid copolymer in our series. Therefore, we suggest that patients with voiding dysfunction be treated at least 6 months before endoscopic therapy with anticholinergics and/or micturition rehabilitation.

KW - Child

KW - Dextrans

KW - Hyaluronic acid

KW - Urinary incontinence

KW - Vesico-ureteral reflux

UR - http://www.scopus.com/inward/record.url?scp=0036784293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036784293&partnerID=8YFLogxK

M3 - Article

VL - 168

SP - 1695

EP - 1698

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4 II

ER -